2 Information about cenegermin

2 Information about cenegermin

Marketing authorisation indication

Cenegermin (Oxervate, Dompé) is indicated for the 'treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults'.

Dosage in the marketing authorisation

The recommended dose of cenegermin is 1 drop (20 mcg/ml) 6 times a day at 2-hourly intervals (starting from the morning and within 12 hours), for 8 weeks.


£14,500 for 8-week course of treatment (company submission).

The company has a commercial agreement which would apply if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)